Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Although p16 protein expression, a surrogate marker of oncogenic human papillomavirus (HPV) infection, is recognized as a prognostic marker in oropharyngeal squamous cell carcinoma (OPSCC), its ...

The 14-gene assay identified patients with molecular high risk who benefitted from adjuvant chemotherapy. Use of the assay to determine eligibility for adjuvant therapy in stage IA–IIA non-squamous ...

Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma prior to surgery. ClinicalTrials.gov. Updated October 26, 2022.

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Squamous-cell carcinoma is one of the most common cancers in humans. Most cases are localized and treatable; the small percentage that recur or spread can be fatal. Immunocompromised patients are a ...

Squamous cell carcinoma of the penis is a rare and biologically aggressive malignancy, characterized by limited treatment options, not always curative, but just palliative in the advanced stage (20).

First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previo ...

Keywords: oral squamous cell carcinoma, AJCC classification, number of positive lymph nodes, survival analysis, p16 Citation: Li P, Fang Q, Yang Y, Chen D, Du W, Liu F and Luo R (2021) Survival ...

By definition, invasive squamous cell carcinoma will demonstrate tumor nests invading into the dermis, frequently with associated lymphocytic inflammation. Well-differentiated squamous cell carcinoma ...